Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.

@article{Weber2006PamidronateDN,
  title={Pamidronate does not adversely affect bone intrinsic material properties in children with osteogenesis imperfecta.},
  author={Michael Weber and Paul Roschger and Nadja Fratzl-Zelman and Thomas Sch{\"o}berl and Frank Rauch and Francis H Glorieux and Peter Fratzl and Klaus Klaushofer},
  journal={Bone},
  year={2006},
  volume={39 3},
  pages={
          616-22
        }
}
Cyclical intravenous pamidronate therapy increases bone mass in children with osteogenesis imperfecta (OI), but the effect on the intrinsic material properties of bone is unknown at present. Thus, a possible influence of pamidronate treatment on bone quality at the material level might negate the beneficial effects of the gain in bone mass and lead to bone fragility in the long term. In the present study, we used transiliac bone biopsy samples and assessed the intrinsic material properties of… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 40 CITATIONS

References

Publications referenced by this paper.
SHOWING 1-10 OF 37 REFERENCES

from growing osteogenesis imperfecta and wild - type mouse

  • JY Rho, TY Tsui, GM Pharr
  • 2005

Similar Papers

Loading similar papers…